A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple Myeloma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Robert Knight, MD
Celgene Therapeutic Area Head
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- the Mater Private Centre for Haematology & Oncology
South Brisbane, Australia
- Wilhelminenspital
Vienna, Montlearstrasse 37, Austria
- St James'S Hospital
Dublin, Ireland
- H. Clínico de Salamanca
Salamanca, Spain
- Royal Free Hospital & Medical School
London, United Kingdom
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 30 Nov 2006
- Primary completion
- 31 Oct 2009
- Completion
- 30 Nov 2009
- Last update posted
- 21 May 2012
- Registered enrollment
- 587
- Registry id
- NCT00420849
Cross-registrations
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.